ViiV Healthcare submits New Drug Application to the FDA for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available
ViiV Healthcare completed submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA).
